PMC:7195088 / 9887-11457 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"170","span":{"begin":169,"end":177},"obj":"Species"},{"id":"171","span":{"begin":356,"end":364},"obj":"Species"},{"id":"172","span":{"begin":705,"end":713},"obj":"Species"},{"id":"173","span":{"begin":1384,"end":1392},"obj":"Species"},{"id":"204","span":{"begin":154,"end":165},"obj":"Chemical"},{"id":"205","span":{"begin":636,"end":647},"obj":"Chemical"},{"id":"242","span":{"begin":183,"end":191},"obj":"Disease"},{"id":"243","span":{"begin":347,"end":355},"obj":"Disease"},{"id":"244","span":{"begin":563,"end":573},"obj":"Disease"},{"id":"245","span":{"begin":677,"end":685},"obj":"Disease"},{"id":"246","span":{"begin":1529,"end":1537},"obj":"Disease"}],"attributes":[{"id":"A170","pred":"tao:has_database_id","subj":"170","obj":"Tax:9606"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"Tax:9606"},{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Tax:9606"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"Tax:9606"},{"id":"A204","pred":"tao:has_database_id","subj":"204","obj":"MESH:C502936"},{"id":"A205","pred":"tao:has_database_id","subj":"205","obj":"MESH:C502936"},{"id":"A242","pred":"tao:has_database_id","subj":"242","obj":"MESH:C000657245"},{"id":"A243","pred":"tao:has_database_id","subj":"243","obj":"MESH:C000657245"},{"id":"A244","pred":"tao:has_database_id","subj":"244","obj":"MESH:D007239"},{"id":"A245","pred":"tao:has_database_id","subj":"245","obj":"MESH:C000657245"},{"id":"A246","pred":"tao:has_database_id","subj":"246","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Question 6. Should other immunosuppressive and/or immunomodulatory therapies be administered? Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival. In the absence of clinical studies, we suggest to preferentially administer also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) within RCT. This also applies to modifications of the immune response through high-dose intravenous immunoglobulins or plasma from convalescent patients, which, although promising in small case series, both deserve dedicated RCT investigation to clearly understand their role in impacting COVID-19 outcomes and their tolerability."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":1340,"end":1355},"obj":"Body_part"},{"id":"T4","span":{"begin":1359,"end":1365},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"Question 6. Should other immunosuppressive and/or immunomodulatory therapies be administered? Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival. In the absence of clinical studies, we suggest to preferentially administer also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) within RCT. This also applies to modifications of the immune response through high-dose intravenous immunoglobulins or plasma from convalescent patients, which, although promising in small case series, both deserve dedicated RCT investigation to clearly understand their role in impacting COVID-19 outcomes and their tolerability."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T51","span":{"begin":183,"end":191},"obj":"Disease"},{"id":"T52","span":{"begin":347,"end":355},"obj":"Disease"},{"id":"T53","span":{"begin":563,"end":573},"obj":"Disease"},{"id":"T54","span":{"begin":677,"end":685},"obj":"Disease"},{"id":"T55","span":{"begin":1529,"end":1537},"obj":"Disease"}],"attributes":[{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A53","pred":"mondo_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A55","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Question 6. Should other immunosuppressive and/or immunomodulatory therapies be administered? Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival. In the absence of clinical studies, we suggest to preferentially administer also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) within RCT. This also applies to modifications of the immune response through high-dose intravenous immunoglobulins or plasma from convalescent patients, which, although promising in small case series, both deserve dedicated RCT investigation to clearly understand their role in impacting COVID-19 outcomes and their tolerability."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T32","span":{"begin":253,"end":258},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T33","span":{"begin":606,"end":607},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T34","span":{"begin":623,"end":628},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T35","span":{"begin":774,"end":775},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T36","span":{"begin":780,"end":784},"obj":"http://purl.obolibrary.org/obo/CLO_0008416"},{"id":"T37","span":{"begin":780,"end":784},"obj":"http://purl.obolibrary.org/obo/CLO_0050081"},{"id":"T38","span":{"begin":914,"end":915},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T39","span":{"begin":1359,"end":1365},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"Question 6. Should other immunosuppressive and/or immunomodulatory therapies be administered? Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival. In the absence of clinical studies, we suggest to preferentially administer also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) within RCT. This also applies to modifications of the immune response through high-dose intravenous immunoglobulins or plasma from convalescent patients, which, although promising in small case series, both deserve dedicated RCT investigation to clearly understand their role in impacting COVID-19 outcomes and their tolerability."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T44","span":{"begin":154,"end":165},"obj":"Chemical"},{"id":"T45","span":{"begin":253,"end":258},"obj":"Chemical"},{"id":"T46","span":{"begin":623,"end":628},"obj":"Chemical"},{"id":"T47","span":{"begin":636,"end":647},"obj":"Chemical"},{"id":"T48","span":{"begin":1221,"end":1238},"obj":"Chemical"},{"id":"T49","span":{"begin":1228,"end":1238},"obj":"Chemical"}],"attributes":[{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_23924"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Question 6. Should other immunosuppressive and/or immunomodulatory therapies be administered? Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival. In the absence of clinical studies, we suggest to preferentially administer also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) within RCT. This also applies to modifications of the immune response through high-dose intravenous immunoglobulins or plasma from convalescent patients, which, although promising in small case series, both deserve dedicated RCT investigation to clearly understand their role in impacting COVID-19 outcomes and their tolerability."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T2","span":{"begin":1294,"end":1309},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Question 6. Should other immunosuppressive and/or immunomodulatory therapies be administered? Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival. In the absence of clinical studies, we suggest to preferentially administer also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) within RCT. This also applies to modifications of the immune response through high-dose intravenous immunoglobulins or plasma from convalescent patients, which, although promising in small case series, both deserve dedicated RCT investigation to clearly understand their role in impacting COVID-19 outcomes and their tolerability."}

{"project":"LitCovid-sentences","denotations":[{"id":"T67","span":{"begin":0,"end":11},"obj":"Sentence"},{"id":"T68","span":{"begin":12,"end":93},"obj":"Sentence"},{"id":"T69","span":{"begin":94,"end":248},"obj":"Sentence"},{"id":"T70","span":{"begin":249,"end":575},"obj":"Sentence"},{"id":"T71","span":{"begin":576,"end":1045},"obj":"Sentence"},{"id":"T72","span":{"begin":1046,"end":1251},"obj":"Sentence"},{"id":"T73","span":{"begin":1252,"end":1570},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Question 6. Should other immunosuppressive and/or immunomodulatory therapies be administered? Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival. In the absence of clinical studies, we suggest to preferentially administer also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) within RCT. This also applies to modifications of the immune response through high-dose intravenous immunoglobulins or plasma from convalescent patients, which, although promising in small case series, both deserve dedicated RCT investigation to clearly understand their role in impacting COVID-19 outcomes and their tolerability."}